Clinical Trial Update: Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study

View source ↗

Summary

This clinical trial update describes a prospective cohort study of conversion therapy for initially unresectable hepatocellular carcinoma using transarterial ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Unresectable Hepatocellular Carcinom | Status: NOT_YET_RECRUITING